Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

08.12.20141484
Experimental data indicate that reducing factor XI levels attenuates thrombosis without causing bleeding, but the role of factor XI in the prevention of postoperative venous thrombosis in humans is unknown. FXI-ASO (ISIS 416858) is a second-generation antisense oligonucleotide that specifically reduces factor XI levels.

Aggressive Risk Factor Reduction Study for Atrial Fibrillation and Implications for the Outcome of Ablation: The ARREST-AF Cohort Study

05.12.20141553
Does aggressive risk factor management (RFM) improve outcomes after catheter ablation of atrial fibrillation (AF)?

Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction

04.12.20141779
What are the comorbidities associated with heart failure with preserved ejection fraction (HFpEF) versus heart failure with reduced ejection fraction (HFrEF)?

Вебинары Европейского общества кардиологов

03.12.20142053
Приглашаем Вас принять участие в бесплатных вебинарах Европейского общества кардиологов.

Rosuvastatin failed to reduce fracture risk in JUPITER analysis

03.12.20141524
Rosuvastatin was not associated with a reduced risk for fracture in men and women with elevated high-sensitivity C-reactive protein enrolled in the JUPITER trial.

Prehospital epinephrine associated with worse outcomes after cardiac arrest

02.12.20141775
In patients who achieved return of spontaneous circulation after cardiac arrest, prehospital use of epinephrine was associated with worse outcomes, according to new findings.
Данный сайт и вся информация на нём предназначена для медицинских работников. Продолжая просмотр, вы соглашаетесь и подтверждаете, что являетесь медицинским работником.